US FDA grants donanemab Breakthrough Therapy designation for Alzheimer’s disease

The designation was based on data from the randomised, placebo-controlled Phase II TRAILBLAZER-ALZ study (n=272), in which it slowed the decline of the Integrated Alzheimer's Disease Rating Scale in patients with early, symptomatic Alzheimer’s disease.

Source:

Biospace Inc.